PDF(Pubmed)
Abstract：
Recently, non-pharmacological treatments are gaining increasing importance for improving the quality of life in patients with chronic obstructive pulmonary disease (COPD). This pilot study aimed to evaluate the feasibility of conducting extensive research on Chuna manual therapy (CMT). This study investigated the effectiveness and safety of CMT adjuvant to Western medicine (WM) in patients with COPD. Forty patients with COPD were randomized into two groups in a 1:1 ratio: experimental (CMT plus WM) and control (WM only) groups. The CMT intervention was administered once a week for eight weeks. The primary outcome measured was the 6-min walk distance (6MWD). Secondary outcomes measured were: forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), assessments using the modified Medical Research Council (mMRC) scale and Visual Analog Scale (VAS) for dyspnea, the COPD Assessment Test (CAT), St. George\'s Respiratory Questionnaire (SGRQ), and the EuroQoL five-dimensional questionnaire (EQ-5D). The mean differences in FEV1 (L) between Weeks 1 and 8 were statistically significant between the groups (p = 0.039). Additionally, the experimental group showed improved 6MWD, mMRC, VAS for dyspnea, CAT, SGRQ (total), and EQ-VAS scores than the control group. However, the differences between the two groups were not statistically significant. No adverse events were observed during this trial. CMT has the potential to alleviate symptoms, improve quality of life, and delay the decline in lung function in patients with COPD. The results of this pilot study could lead to large-scale clinical trials in the future.
摘要：
最近,非药物治疗对于改善慢性阻塞性肺疾病(COPD)患者的生活质量越来越重要.这项初步研究旨在评估对Chuna手动疗法（CMT）进行广泛研究的可行性。这项研究调查了CMT辅助西药（WM）在COPD患者中的有效性和安全性。40例COPD患者以1：1的比例随机分为两组：实验组（CMT加WM）和对照组（仅WM）。CMT干预措施每周一次，持续八周。测量的主要结果是6分钟步行距离（6MWD）。测量的次要结果是：1s用力呼气量（FEV1），强迫肺活量(FVC)，使用改良的医学研究理事会（mMRC）量表和视觉模拟量表（VAS）评估呼吸困难，COPD评估测试（CAT），圣乔治呼吸问卷(SGRQ)，和EuroQoL五维问卷(EQ-5D)。第1周和第8周之间的FEV1（L）的平均差异在组间具有统计学意义（p=0.039）。此外,实验组6MWD有所改善,mMRC,VAS用于呼吸困难，CAT,SGRQ（总计），EQ-VAS评分高于对照组。然而,两组间差异无统计学意义。在该试验期间没有观察到不良事件。CMT有可能缓解症状，提高生活质量,并延缓COPD患者肺功能的下降。这项初步研究的结果可能会导致未来的大规模临床试验。
